BioSpace News Archive

Kintor Pharmaceutical Limited is pleased to update the preliminary analysis of the clinical trial of Proxalutamide for the treatment of COVID-19 patients.

Humanigen, Inc. and EVERSANA announced that they are partnering to make lenzilumab available to hospitalized and hypoxic COVID-19 patients in the event that an Emergency Use Authorization is issued from the U.S.

The end of 2020 marked a turning point for Canada in our fight against COVID-19. We witnessed Canadian approval of the first two vaccines for COVID-19 - the Pfizer-BioNTech vaccine and the Moderna vaccine, and rollout of initial doses of these vaccines across the country.

Expects continued strong financial and operating momentum in 2021, forecasting total revenues of $2 billion at the midpoint and Adjusted EBITDA of $780 million at the midpoint, both increases year-over-year

Dyne Therapeutics, Inc., a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, announced new preclinical data from its myotonic dystrophy type 1 program demonstrating robust RNA knockdown of toxic human nuclear DMPK, the genetic basis of the disease.

Q4 Product and Service Revenue of $35.7 Million, Including GeoMx Revenue of $12.2 million, Exceeding High End of Guidance Ranges

Cabozantinib Franchise Preliminary Net Product Revenue of $200 million for the Fourth Quarter 2020, and $741 million for the Full Year 2020

Atara has had productive interactions with the FDA for ATA188 and is progressing the Phase 2 randomized clinical trial (RCT) toward an interim analysis in H1 2022

Exagen Inc., an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, reported preliminary, unaudited financial results for the quarter ended December 31, 2020.

Sorrento Therapeutics, Inc., announced that Dr. Henry Ji, Chairman and CEO, will participate in the following upcoming conference